These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31944867)

  • 1. Design and optimization of a child-friendly dispersible tablet containing isoniazid, pyrazinamide, and rifampicin for treating tuberculosis in pediatrics.
    Suárez-González J; Santoveña-Estévez A; Soriano M; Fariña JB
    Drug Dev Ind Pharm; 2020 Feb; 46(2):309-317. PubMed ID: 31944867
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
    Battini S; Mannava MKC; Nangia A
    J Pharm Sci; 2018 Jun; 107(6):1667-1679. PubMed ID: 29462633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis.
    Tsiligiannis A; Sfouni M; Nalda-Molina R; Dokoumetzidis A
    Eur J Pharm Sci; 2019 Oct; 138():105016. PubMed ID: 31356869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compatibility Between Four Anti-TB Drugs and Tablet Excipients Determined By Microcalorimetry.
    Aucamp M; Liebenberg W; Okaecwe T; Geldenhuys M; Stieger N
    Pharmazie; 2019 Jun; 74(6):350-351. PubMed ID: 31138372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Design, Characterization and Preliminary Safety Evaluation of an Edible Orodispersible Formulation for Pediatric Tuberculosis Pharmacotherapy.
    Matawo N; Adeleke OA; Wesley-Smith J
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of rifampicin, isoniazid and pyrazinamide in tablet preparations by multivariate spectrophotometric calibration.
    Goicoechea HC; Olivieri AC
    J Pharm Biomed Anal; 1999 Aug; 20(4):681-6. PubMed ID: 10704137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-Processed Excipients for Dispersible Tablets-Part 1: Manufacturability.
    Bowles BJ; Dziemidowicz K; Lopez FL; Orlu M; Tuleu C; Edwards AJ; Ernest TB
    AAPS PharmSciTech; 2018 Aug; 19(6):2598-2609. PubMed ID: 29916193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
    Graham SM; Grzemska M; Gie RP
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():3-8. PubMed ID: 26564534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial neural networks to optimize formulation components of a fixed-dose combination of rifampicin, isoniazid and pyrazinamide in a microemulsion.
    Glass BD; Agatonovic-Kustrin S; Wisch MH
    Curr Drug Discov Technol; 2005 Sep; 2(3):195-201. PubMed ID: 16472228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aceclofenac fast dispersible tablet formulations: Effect of different concentration levels of Avicel PH102 on the compactional, mechanical and drug release characteristics.
    Yasmin R; Shoaib MH; Ahmed FR; Qazi F; Ali H; Zafar F
    PLoS One; 2020; 15(2):e0223201. PubMed ID: 32050259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Milky Way: paediatric milk-based dispersible tablets prepared by direct compression - a proof-of-concept study.
    Orubu SE; Hobson NJ; Basit AW; Tuleu C
    J Pharm Pharmacol; 2017 Apr; 69(4):417-431. PubMed ID: 27349946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of chemometrics to compare NIR and HPLC for the simultaneous determination of drug levels in fixed-dose combination tablets employed in tuberculosis treatment.
    Teixeira KSS; da Cruz Fonseca SG; de Moura LCB; de Moura MLR; Borges MHP; Barbosa EG; De Lima E Moura TFA
    J Pharm Biomed Anal; 2018 Feb; 149():557-563. PubMed ID: 29197297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S343-6; discussion S351-2. PubMed ID: 10593715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.